Funding for this research was provided by:
Basilea Pharmaceutica International Ltd., Basel, Switzerland
Received: 4 September 2018
Accepted: 14 February 2019
First Online: 26 February 2019
Ethics approval and consent to participate
: Both studies were conducted in accordance with International Conference on Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and applicable local regulations. Each study protocol was approved by an Independent Ethics Committee, and all patients provided written informed consent before any study procedures were carried out.
: Not applicable.
: KH is an employee of Basilea Pharmaceutica Ltd. ME is an employee of Basilea Pharmaceutica Ltd. AS-H was previously an employee of Basilea Pharmaceutica Ltd. MS is an employee of Icon plc, who were paid by Basilea Pharmaceutica Ltd. to perform the statistical analyses for this study. TW received fees from AstraZeneca, Basilea Pharmaceutica Ltd. and Pfizer for lectures in relation to this study, and fees from AstraZeneca, Bayer AG, Basilea Pharmaceutica Ltd., Merck Sharp & Dohme, Novartis AG and Pfizer for lectures and advisory boards unrelated to this study during the 36 months prior to publication of this article. TWLS has no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.